Dr. Abedin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9200 W Wisconsin Ave
Milwaukee, WI 53226- Is this information wrong?
Summary
- Dr. Sameem Abedin is an oncologist in Milwaukee, WI and is affiliated with Froedtert and the Medical College of Wisconsin Froedtert Hospital. He received his medical degree from Sidney Kimmel Medical College and has been in practice 8 years. He specializes in hematologic oncology, specifically leukemia, myelodysplastic syndrome, and allogeneic transplantation.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2009
Certifications & Licensure
WI State Medical License 2017 - 2025
IL State Medical License 2014 - 2017
MI State Medical License 2012 - 2016
PA State Medical License 2009 - 2012
Clinical Trials
- A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies Start of enrollment: 2017 Mar 20
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2018 Feb 02
- NLA101 in Adults Receiving High Dose Chemotherapy for AML Start of enrollment: 2018 Jan 24
- Join now to see all
Publications & Presentations
PubMed
- A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hi...> ;Haematologica. 2024 Apr 4
- 2 citationsEfficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohor...Muhammad Bilal Abid, Micah Rubin, Aniko Szabo, Walter Longo, Timothy S Fenske, Cole McCoy, Aaron Lorge, Sameem Abedin, Anita D'Souza, Binod Dhakal, Nirav N Shah, Mehdi...> ;Transplantation and Cellular Therapy. 2024 Mar 1
- Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogen...Chhabra, S., Jerkins, J., Monahan, K., Szabo, A., Shah, N., Abedin, S., Runaas, L., Fenske, T., Pasquini, M., Shaw, B., Drobyski, W., Saber, W., D'Souza, A., Dhakal, B...> ;Bone Marrow Transplantation. 2024 Mar 1
- Join now to see all
Abstracts/Posters
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASHDecember 12th, 2022- Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-a CLAG-M Combination TrialNovember 3rd, 2022
- Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-a in Combination with CLAG-M for Patients with Relapsed or Refractory AMLDecember 14th, 2021
- Join now to see all
Hospital Affiliations
Froedtert and the Medical College of Wisconsin Froedtert HospitalMilwaukee, Wisconsin
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
